BriaCell Therapeutics (NASDAQ:BCTX, BCTXW;TSX:BCT) is a scientific section biotechnology firm growing revolutionary immunotherapies for treating most cancers.
With a recently-awarded Quick Monitor standing from the FDA, BriaCell’s lead candidate, Bria-IMT™, is an immunotherapy at the moment being developed to deal with superior breast most cancers, which is the anticipated reason behind over 43,000 deaths within the US in 2022. Bria-IMT™achieved optimistic proof of idea, exhibiting excellent security and efficacy knowledge. Importantly, preliminary efficacy knowledge was related, or superior to, these of different accredited breast most cancers medication once they have been at the same stage of scientific improvement. After important success, BriaCell acquired FDA Quick Monitor designation for this focused immunotherapy strategy.
Firm Highlights
- April 2022: BriaCell receives FDA fast-track approval for focused breast most cancers immunotherapy.
- February 2022: BriaCell appoints famend oncologist, Dr. Giuseppe Del Priore as chief medical officer, appoints immunologist Dr. Alexander Kharazi to its advisory board, and provides two scientific trial websites to speed up affected person enrollment.
- December 2021: BriaCell proclaims insiders’ intention to buy as much as 10 % of public market securities.
- September 2021: BriaCell proclaims securities buyback to buy as much as 10 % of widespread shares and as much as 10 % of listed warrants.
- July 2021: BriaCell Part I/IIa scientific trial mixture research in superior breast most cancers sufferers opens for enrollment.
- June 2021: BriaCell Therapeutics proclaims closing of US$27.2 million non-public placement
- June 2021: BriaCell Studies 12.0 months general survival profit in superior breast most cancers; 100% decision of ‘eye-bulging’ tumor
- February 2021: BriaCell proclaims closing of US$25 million public providing and itemizing on NASDAQ.
This BriaCell Therapeutics firm profile is a part of a paid investor schooling campaitn.*
